Item 8.01. Other Events.

As previously disclosed, on December 11, 2020, a purported stockholder derivative complaint (the "Derivative Action") was filed by plaintiff Leo Shumacher against Iovance Biotherapeutics, Inc. (the "Company"), as nominal defendant, and certain of its current officers and directors, as defendants, in the Court of Chancery in the State of Delaware. On June 15, 2022, the parties agreed to a proposed settlement, set forth in a Stipulation of Compromise and Settlement (the "Stipulation"), which was submitted to the Court for approval. The Stipulation calls for the Company to adopt certain governance changes and for the Company to pay to plaintiff's counsel $400,000 for certain legal fees and expenses.

On August 26, 2022, the Court entered a Scheduling Order setting a hearing to determine whether final approval will be given to the settlement. The hearing has been set for November 17, 2022 at 3:15 p.m. in the Leonard L. Williams Justice Center, 500 North King Street, Wilmington, Delaware 19801. As required by the Scheduling Order, the Company is filing the Notice of Pendency of Settlement of Action (the "Notice") with this Current Report on Form 8-K, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits.



Exhibit
  No.                                   Description
  99.1       Notice of Pendency of Settlement of Action, dated August 31, 2022.
  104      Cover Page Interactive Data File (embedded as Inline XBRL document)

© Edgar Online, source Glimpses